From triple agonists to mitochondrial peptides, these are the compounds driving modern metabolic research. Here's what makes each one unique and how they compare.
Part of the PeptidesATX Research Hub
Metabolic research has undergone a paradigm shift in recent years. The discovery that gut-derived incretin hormones, growth hormone axis peptides, and mitochondrial-encoded signaling molecules can profoundly influence energy balance and lipid metabolism has opened entirely new avenues of scientific investigation.
The peptides below represent the most actively researched compounds in metabolic and fat loss studies. Each operates through distinct receptor systems and signaling pathways, providing researchers with a diverse toolkit for probing metabolic function at the molecular level.
Retatrutide is the most comprehensive incretin-based research compound currently available. As a triple agonist, it simultaneously activates three receptor systems that individually have well-established roles in metabolic regulation:
The glucagon receptor component is what fundamentally distinguishes Retatrutide from dual agonists like Tirzepatide. Glucagon receptor activation drives hepatic lipid oxidation and increases energy expenditure — mechanisms that are absent in GLP-1/GIP-only compounds. Preclinical and early clinical research has shown that this triple mechanism produces metabolic effects that exceed those observed with single or dual agonist compounds.
Retatrutide is available in 5mg, 10mg, and 30mg vials, each with batch-specific Certificate of Analysis.
View Retatrutide →Tirzepatide is a dual incretin agonist that targets both GLP-1 and GIP receptors. It was the first dual-action incretin compound to demonstrate clinically meaningful metabolic effects, and it has become one of the most widely studied peptides in metabolic research.
The dual mechanism provides complementary metabolic signaling. GLP-1 receptor activation drives the primary effects on appetite regulation and glucose homeostasis, while GIP receptor co-activation enhances insulin sensitivity and influences lipid handling in adipose tissue. Research suggests that the combined activation of both pathways produces effects greater than GLP-1 agonism alone.
Tirzepatide's structure includes a C20 fatty diacid moiety that enables albumin binding, extending its pharmacokinetic half-life and allowing once-weekly dosing in research protocols. This structural feature makes it particularly practical for longitudinal studies where consistent exposure levels are important.
Available in 10mg and 30mg vials with third-party purity verification.
View Tirzepatide →Semaglutide is a selective GLP-1 receptor agonist and one of the most extensively characterized peptides in metabolic research. With the largest body of published clinical trial data among incretin peptides, Semaglutide serves as the reference standard against which newer dual and triple agonists are often compared.
Its mechanism centers on GLP-1 receptor activation, which produces effects on glucose-dependent insulin secretion, gastric motility, and hypothalamic appetite regulation. Semaglutide incorporates structural modifications (including an amino acid substitution at position 8 and a C18 fatty acid chain) that provide resistance to DPP-4 enzymatic degradation and enable extended pharmacokinetic profiles.
For research purposes, Semaglutide is particularly valuable as a comparator compound. Its well-characterized pharmacology makes it an essential control when studying novel incretin agonists or investigating the added value of multi-receptor activation.
View Semaglutide →MOTS-C represents a completely different approach to metabolic research. Rather than targeting gut hormone receptors like the incretin peptides above, MOTS-C is a mitochondrial-derived peptide that directly influences cellular energy metabolism through the AMPK signaling pathway.
Encoded by mitochondrial DNA (a rarity among known bioactive peptides), MOTS-C activates AMP-activated protein kinase — the cell's master energy sensor. AMPK activation triggers a cascade of metabolic adjustments including enhanced glucose uptake, increased fatty acid oxidation, and suppression of energy-consuming biosynthetic processes.
Research has also revealed exercise-mimetic properties: MOTS-C activates many of the same metabolic pathways that are typically induced by physical activity, and endogenous MOTS-C levels increase in response to exercise. Additionally, MOTS-C levels decline with age, paralleling the age-related decline in mitochondrial function and metabolic efficiency.
These properties make MOTS-C a uniquely valuable research tool for studying cellular energy regulation, mitochondrial communication, and the molecular mechanisms underlying metabolic adaptation.
View MOTS-C 10mg →Tesamorelin operates through an entirely different axis than the incretin and mitochondrial peptides. As a synthetic analog of Growth Hormone Releasing Hormone (GHRH), Tesamorelin stimulates the anterior pituitary to release endogenous growth hormone, which in turn activates the GH/IGF-1 axis.
The GH/IGF-1 axis has well-documented effects on body composition through multiple mechanisms: growth hormone promotes lipolysis (fat breakdown), increases protein synthesis, and shifts nutrient partitioning toward lean tissue accretion. Tesamorelin's approach of stimulating endogenous GH release (rather than administering exogenous GH directly) preserves the pulsatile secretion pattern and physiological feedback regulation of the growth hormone axis.
In research contexts, Tesamorelin is studied for its effects on visceral adipose tissue specifically. Unlike subcutaneous fat, visceral fat is metabolically active and produces inflammatory cytokines. Research has focused on how GHRH-stimulated GH release affects visceral fat distribution, hepatic lipid content, and related metabolic markers.
Available in 10mg vials with third-party purity testing and batch-specific COA.
View Tesamorelin →Understanding how these peptides differ at the pathway level is essential for designing effective research protocols:
These pathways are largely non-overlapping, which is why research groups studying metabolic function often work with compounds from multiple categories to build a comprehensive understanding of energy regulation.
The most studied peptides in metabolic research include Retatrutide (triple agonist), Tirzepatide (dual agonist), Semaglutide (GLP-1 agonist), MOTS-C (mitochondrial peptide), and Tesamorelin (GHRH analog). Each targets different metabolic pathways.
Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously, while Tirzepatide targets only GLP-1 and GIP. The glucagon receptor component in Retatrutide drives additional hepatic lipid oxidation and energy expenditure not present in Tirzepatide's mechanism.
MOTS-C is a mitochondrial-derived peptide that activates AMPK, the cell's master energy sensor. It influences glucose metabolism, fatty acid oxidation, and cellular energy balance through both AMPK-dependent and independent mechanisms.
Tesamorelin stimulates endogenous growth hormone release via the GH/IGF-1 axis, influencing lipid metabolism through growth hormone-mediated pathways. Incretin peptides act on gut hormone receptors to regulate insulin, appetite, and gastric function.
PeptidesATX carries the full range of metabolic research compounds with third-party purity testing and batch-specific COAs. Same-day shipping from Austin, TX.
Disclaimer: All compounds referenced in this article are intended for laboratory research use only. They are not approved for human or veterinary use.